Loading organizations...
§ Private Profile · Santa Clara, CA, USA
Zeto is a technology company.
Zeto develops an innovative, cloud-based wireless electroencephalography (EEG) system designed to transform brain monitoring. Its core product features a dry EEG headset, streamlining the traditional EEG process by enhancing accessibility and ease of use. This system integrates an AI-driven cloud platform, providing a modern approach to neurological diagnostics and data management for healthcare providers.
The company was founded by Aswin Gunasekar, whose vision aimed to significantly improve and simplify EEG access. Gunasekar recognized the inefficiencies and complexities inherent in conventional EEG setups, inspiring the creation of a more user-friendly and portable solution. This insight positioned Zeto to address critical gaps in neurological monitoring, making sophisticated diagnostic tools more practical for a wider range of clinical environments.
Zeto’s products are utilized by hospitals and clinics, serving both inpatient and outpatient settings across the United States. The company is committed to dramatically improving EEG access, ultimately making advanced brain monitoring more readily available. Its long-term vision centers on redefining electroencephalogram diagnostics, ensuring that essential neurological assessments can be performed efficiently and effectively wherever needed.
Zeto has raised $38.0M across 2 funding rounds.
Zeto has raised $38.0M in total across 2 funding rounds.
Zeto has raised $38.0M in total across 2 funding rounds.
Zeto's investors include Tuff Yen, Foothill Ventures (formerly Tsingyuan Ventures), Quest Venture Partners, Maarten 't Hooft, Aphelion Capital, ShangBay Capital, SV Tech Ventures.
Zeto has raised $38.0M across 2 funding rounds. Most recently, it raised $31.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2025 | $31M Series B | — | — | Announced |
| Jan 1, 2020 | $7M Series A | Tuff YEN | Foothill Ventures (formerly Tsingyuan Ventures), Quest Venture Partners, Maarten 'T Hooft, Aphelion Capital, ShangBay Capital, SV Tech Ventures | Announced |
Zeto, Inc. is a medical technology company developing wearable EEG (electroencephalography) headsets and a cloud-based platform to modernize brain monitoring for healthcare providers. It serves hospitals, clinics, ICUs, emergency departments, physician offices, and home settings, solving the problems of traditional EEG's complexity, preparation time, and limited accessibility by offering zero-prep, wireless devices with AI-driven seizure detection, remote neurologist interpretation, and video monitoring[1][2][5]. Zeto targets conditions like epilepsy, seizures, stroke, depression, and traumatic brain injury, with strong growth evidenced by its ranking on the 2024 Inc. 5000 list of America's fastest-growing private companies, FDA clearances in 2018 and 2024 for products like Zeto ONE, and a $31 million Series B funding round in January 2025 that brings total funding to $38.3 million[1][2][3].
Founded in 2014 in Santa Clara, California, by Aswin Gunasekar, who serves as CEO, Zeto emerged to address the outdated, labor-intensive nature of traditional EEG procedures requiring skin abrasion, conductive paste, and wired setups[2][4]. Gunasekar's vision was to transform EEG into a 21st-century solution using revolutionary FDA-cleared wireless headsets and cloud technology, initially focusing on hospitals and clinics[1][2]. Early traction came from FDA clearance in 2018, followed by pivotal milestones like the 2024 launch of next-generation Zeto ONE (cleared for hospital, home, ambulance, and air transport use) and rapid adoption by U.S. healthcare institutions, culminating in the 2025 Series B funding led by MindWorks Global[1][3].
Zeto stands out in EEG monitoring through these key advantages:
Zeto rides the wave of AI-driven medtech and telehealth expansion, capitalizing on post-pandemic demand for remote, accessible diagnostics amid neurologist shortages and rising neurological disorder prevalence (e.g., epilepsy affects millions)[1][3][5]. Timing aligns with FDA's support for innovative wearables, enabling EEG in non-traditional settings like homes and ambulances, which reduces patient transfers and hospital burdens[1][2][5]. Market forces favoring Zeto include a massive untapped potential in outpatient/home monitoring and AI for early detection, positioning it to influence ecosystem shifts toward decentralized neurocare and better outcomes in critical conditions[1][3].
Zeto's trajectory points to accelerated commercialization post-$31M Series B, with plans to scale sales teams, R&D for expanded AI detections (e.g., depression, TBI), and deeper healthcare partnerships[3]. Trends like AI diagnostics, wearable medtech, and value-based care will propel growth, potentially evolving Zeto into a dominant player in noninvasive brain health as adoption surges in underserved areas. This builds on its Inc. 5000 momentum, redefining EEG from a cumbersome test to an always-on, accessible vital sign[1][3].